News

After President Donald Trump told reporters he underwent an MRI—adding that the results were “perfect”—it remains unclear why, exactly, the scan was ordered in the first place.

heart drugs with stethoscope

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

Cardiovascular Research Foundation is merging with Fogarty Innovation

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

Christian M. Spaulding, MD, PhD, at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

Medtronic Stedi Extra Support guidewire

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

Dr. Nee Khoo, director of the echocardiography lab, Stollery Children’s Hospital, Edmonton, Canada, explains the rapidly growing adoption of pediatric 3D transesophageal echo (TEE) to not only preplan, but also guide and assess the results of congenital heart surgeries.

Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.

Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.

Performing valve-in-valve transcatheter mitral valve replacement (ViV TMVR) with conscious sedation (CS) or monitored anesthesia care (MAC) instead of general anesthesia (GA) is safe and effective, according to new research published in JACC: Cardiovascular Interventions.

During valve-in-valve TMVR, patients are treated with conscious sedation or monitored anesthesia care instead of general anesthesia. This new analysis confirms that the change does not impact patient outcomes, but it was linked to a shorter length of stay.

Left, coronary CT angiography of a vessel showing plaque heavy calcium burden. Right, image showing color code of various types of plaque morphology showing the complexity of these lesions. The right image was processed using the FDA cleared, AI-enabled plaque assessment from Elucid.

New artificial intelligence software that can evaluate coronary CT scans to automatically assess soft plaques were by far the biggest technology advance discussed at the Society of Cardiovascular Computed Tomography (SCCT) 2022 meeting. 

Subclinical leaflet thrombosis after TAVR CT JAMA Cardiology OAC

Treating subclinical leaflet thrombosis after TAVR has been an ongoing challenge for structural heart clinicians, but recent research has gone a long way toward improving our understanding of this important topic. 

LaPrincess Brewer, M.D., a Mayo Clinic preventive cardiologist and principal investigator of the study, explains a heart model.

A new trial for participants from 16 church groups in Minnesota showed that app users significantly improved their heart health scores after just 10 weeks.

Around the web

Researchers recently used advanced 4D flow MRI to track blood in a pulsating artificial heart, revealing dynamics that closely mirror those of a healthy human organ.

Congress needs to act soon to extend telemedicine services that were greatly expanded under COVID provisions, or they will expire by October. Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains concerns raised by doctors and lawmakers.

 

Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains the political and patient care issues involved with ending Affordable Care Act subsidies.